Praxis Precision Medicines and Remagine Labs enter licensing and research collaboration

Corporate ActionRegulation
โดย Insider Monkey·Read original
Summary · why it matters

Praxis Precision Medicines Inc. and Remagine Labs disclosed a research partnership and license agreement to design an iontophoretic transdermal patch for the delivery of ulixacaltamide, a strongly targeted T-type calcium channel inhibitor in development for essential tremor. Both companies will use Remagine's platform for precise, multi-day sustained skin-based dosing to support Praxis's oral program. Separately, on June 29, Praxis announced that the FDA extended the NDA review for relutrigine by three months, moving the PDUFA target date from September 27 to December 27, after the company submitted additional sensitivity analyses labeled as a major amendment. No new clinical trials were requested, and no safety or manufacturing issues were raised.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Praxis Precision Medicines Inc
PRAX
▲ PositiveTechnologyRegulationrelevance

Licensing and research collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide, advancing delivery technology.

Off-coverage companies 1

Remagine LabsPrivate▲ Positive
Technologyrelevance

Entered licensing and research collaboration with Praxis to apply its platform for transdermal delivery of ulixacaltamide.

© 2026 MarketDXNews